Deciphera Pharmaceuticals, Inc. (DCPH)

14,67 +0,09 (+0,62%) Al cierre: 04:00PM EDT

Deciphera Pharmaceuticals, Inc.

200 Smith Street
Waltham, MA 02451
United States
781 209 6400
https://www.deciphera.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 355

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Steven L. Hoerter	President, CEO & Director	1,24M	N/A	1971
Mr. Thomas Patrick Kelly J.D.	Executive VP, CFO & Treasurer	778,85k	N/A	1971
Mr. Daniel C. Martin	Senior VP & Chief Commercial Officer	711,42k	N/A	1975
Dr. Matthew L. Sherman M.D.	Executive VP & Chief Medical Officer	865,62k	N/A	1956
Dr. Kevin Brodbeck Ph.D.	Senior VP & Chief Technical Officer	N/A	N/A	N/A
Dr. Dashyant Dhanak Ph.D.	Executive VP & Chief Scientific Officer	N/A	N/A	1961
Jennifer Larson	Senior Vice President of Finance & Investor Relations	N/A	N/A	N/A
Mr. Jeffrey M. Held J.D.	Senior VP & General Counsel	N/A	N/A	N/A
Ms. Lisa Amaya Price	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A
Ms. Jama Pitman	Senior VP & Chief Development Officer	N/A	N/A	1980

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Deciphera Pharmaceuticals, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 7; Tablero: 6; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.